JPH09502431A - 治療薬剤としての二環式芳香族化合物 - Google Patents
治療薬剤としての二環式芳香族化合物Info
- Publication number
- JPH09502431A JPH09502431A JP7508440A JP50844095A JPH09502431A JP H09502431 A JPH09502431 A JP H09502431A JP 7508440 A JP7508440 A JP 7508440A JP 50844095 A JP50844095 A JP 50844095A JP H09502431 A JPH09502431 A JP H09502431A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- carbon atoms
- compound
- group
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 Bicyclic aromatic compounds Chemical class 0.000 title claims abstract description 120
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229940124597 therapeutic agent Drugs 0.000 title description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 107
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 20
- 125000005843 halogen group Chemical group 0.000 claims abstract description 17
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 12
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 10
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 8
- 230000036506 anxiety Effects 0.000 claims abstract description 8
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims abstract description 8
- 208000008589 Obesity Diseases 0.000 claims abstract description 7
- 206010034010 Parkinsonism Diseases 0.000 claims abstract description 7
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 7
- 235000020824 obesity Nutrition 0.000 claims abstract description 7
- 125000001424 substituent group Chemical group 0.000 claims abstract description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
- 201000003152 motion sickness Diseases 0.000 claims abstract description 5
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 5
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 3
- 125000003277 amino group Chemical group 0.000 claims abstract description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims description 242
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 41
- 239000003638 chemical reducing agent Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 229910052720 vanadium Inorganic materials 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229910052770 Uranium Inorganic materials 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 150000002466 imines Chemical class 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- LTWGNOKBPCXOOT-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-(1-pyridin-2-ylpiperidin-4-yl)methanamine Chemical compound C1OC2=CC=CC=C2OC1CNCC(CC1)CCN1C1=CC=CC=N1 LTWGNOKBPCXOOT-UHFFFAOYSA-N 0.000 claims description 3
- VOHRNHMSMCXPTR-UHFFFAOYSA-N n-[(5-methoxy-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=C(OC)C=CC=C3OC2)CC1 VOHRNHMSMCXPTR-UHFFFAOYSA-N 0.000 claims description 3
- VECANYISKSOUJK-UHFFFAOYSA-N n-[(6-chloro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=CC=C(Cl)C=C3OC2)CC1 VECANYISKSOUJK-UHFFFAOYSA-N 0.000 claims description 3
- QHLRKDSRGUZHSH-UHFFFAOYSA-N n-[(6-chloro-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=CC(Cl)=CC=C3OC2)CC1 QHLRKDSRGUZHSH-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 claims description 2
- SCPMIALDEGNNQC-UHFFFAOYSA-N 1-[1-(2,3-dihydro-1-benzofuran-7-yl)piperidin-4-yl]-n-[(5-methoxy-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]methanamine Chemical compound O1C=2C(OC)=CC=CC=2OCC1CNCC(CC1)CCN1C1=CC=CC2=C1OCC2 SCPMIALDEGNNQC-UHFFFAOYSA-N 0.000 claims description 2
- CHBUDRVHEPFQKH-UHFFFAOYSA-N 3-[[[1-(2-methoxyphenyl)piperidin-4-yl]methylamino]methyl]-2,3-dihydro-1,4-benzodioxin-5-ol Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=C(O)C=CC=C3OC2)CC1 CHBUDRVHEPFQKH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- QYIVXYLXNBZISL-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-(1-pyrazin-2-ylpiperidin-4-yl)methanamine Chemical compound C1OC2=CC=CC=C2OC1CNCC(CC1)CCN1C1=CN=CC=N1 QYIVXYLXNBZISL-UHFFFAOYSA-N 0.000 claims description 2
- DIPCVHNBWIDIIZ-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-(1-quinazolin-4-ylpiperidin-4-yl)methanamine Chemical compound C1=CC=C2C(N3CCC(CC3)CNCC3OC4=CC=CC=C4OC3)=NC=NC2=C1 DIPCVHNBWIDIIZ-UHFFFAOYSA-N 0.000 claims description 2
- OGFDOBGWVXITBG-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-[1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-yl]methanamine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1CNCC1OC2=CC=CC=C2OC1 OGFDOBGWVXITBG-UHFFFAOYSA-N 0.000 claims description 2
- ISUGNHPDTHCDFB-UHFFFAOYSA-N n-(2,3-dihydrobenzo[h][1,4]benzodioxin-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=C4C=CC=CC4=CC=C3OC2)CC1 ISUGNHPDTHCDFB-UHFFFAOYSA-N 0.000 claims description 2
- LCBNYESLHUNVRV-UHFFFAOYSA-N n-[(5-fluoro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=CC=CC(F)=C3OC2)CC1 LCBNYESLHUNVRV-UHFFFAOYSA-N 0.000 claims description 2
- MVTOIWYCUADBKD-UHFFFAOYSA-N n-[(5-fluoro-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=C(F)C=CC=C3OC2)CC1 MVTOIWYCUADBKD-UHFFFAOYSA-N 0.000 claims description 2
- XYBADQIMVGSILK-SFHVURJKSA-N n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNC[C@@H]2OC3=CC=CC=C3OC2)CC1 XYBADQIMVGSILK-SFHVURJKSA-N 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 1
- 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 claims 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- BJNKCHKUCDZMKD-UHFFFAOYSA-N n-[(6,7-dichloro-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=CC(Cl)=C(Cl)C=C3OC2)CC1 BJNKCHKUCDZMKD-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 208000022540 Consciousness disease Diseases 0.000 abstract description 4
- 206010010774 Constipation Diseases 0.000 abstract description 4
- 206010010904 Convulsion Diseases 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 206010033664 Panic attack Diseases 0.000 abstract description 4
- 206010039966 Senile dementia Diseases 0.000 abstract description 4
- 201000001880 Sexual dysfunction Diseases 0.000 abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 4
- 230000036461 convulsion Effects 0.000 abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 208000019906 panic disease Diseases 0.000 abstract description 4
- 231100000872 sexual dysfunction Toxicity 0.000 abstract description 4
- 208000011117 substance-related disease Diseases 0.000 abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract description 3
- 208000022531 anorexia Diseases 0.000 abstract description 3
- 206010003119 arrhythmia Diseases 0.000 abstract description 3
- 230000006793 arrhythmia Effects 0.000 abstract description 3
- 208000015114 central nervous system disease Diseases 0.000 abstract description 3
- 206010061428 decreased appetite Diseases 0.000 abstract description 3
- 208000015706 neuroendocrine disease Diseases 0.000 abstract description 3
- 201000009032 substance abuse Diseases 0.000 abstract description 3
- 231100000736 substance abuse Toxicity 0.000 abstract description 3
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 249
- 239000000203 mixture Substances 0.000 description 229
- 239000007787 solid Substances 0.000 description 168
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 155
- 239000002904 solvent Substances 0.000 description 148
- 239000000243 solution Substances 0.000 description 117
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 99
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 98
- 239000003921 oil Substances 0.000 description 98
- 235000019198 oils Nutrition 0.000 description 98
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 96
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 93
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 85
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 80
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 80
- 239000000047 product Substances 0.000 description 76
- 238000001914 filtration Methods 0.000 description 69
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 68
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- 238000010992 reflux Methods 0.000 description 54
- 239000000284 extract Substances 0.000 description 51
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 39
- 235000019341 magnesium sulphate Nutrition 0.000 description 39
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 37
- 239000000377 silicon dioxide Substances 0.000 description 35
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 34
- 238000002844 melting Methods 0.000 description 34
- 230000008018 melting Effects 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 239000003446 ligand Substances 0.000 description 32
- 229910000027 potassium carbonate Inorganic materials 0.000 description 32
- 239000003480 eluent Substances 0.000 description 30
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 29
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 29
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 25
- 239000002585 base Substances 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 238000003818 flash chromatography Methods 0.000 description 25
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 24
- 239000000725 suspension Substances 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 22
- 238000003756 stirring Methods 0.000 description 21
- 239000003054 catalyst Substances 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 19
- 238000001035 drying Methods 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 239000012258 stirred mixture Substances 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 17
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 16
- 239000012299 nitrogen atmosphere Substances 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 15
- 238000009835 boiling Methods 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 14
- 235000019502 Orange oil Nutrition 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000010502 orange oil Substances 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 12
- 230000008025 crystallization Effects 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 230000009870 specific binding Effects 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 239000012280 lithium aluminium hydride Substances 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108060003345 Adrenergic Receptor Proteins 0.000 description 6
- 102000017910 Adrenergic receptor Human genes 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001491 aromatic compounds Chemical class 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- HIOBFQOMFBWKAT-UHFFFAOYSA-N 1-(2,4-dinitrophenyl)pyridin-1-ium-4-carboxamide;chloride Chemical compound [Cl-].C1=CC(C(=O)N)=CC=[N+]1C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HIOBFQOMFBWKAT-UHFFFAOYSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 4
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 4
- 150000005749 2-halopyridines Chemical class 0.000 description 4
- ASHGTJPOSUFTGB-UHFFFAOYSA-N 3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1 ASHGTJPOSUFTGB-UHFFFAOYSA-N 0.000 description 4
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000011928 denatured alcohol Substances 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- RPHFGEHBXPSYLK-UHFFFAOYSA-N methanamine;dihydrochloride Chemical compound Cl.Cl.NC RPHFGEHBXPSYLK-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- OTGAYUCEDFKLHW-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1OC2=CC=CC=C2OC1 OTGAYUCEDFKLHW-UHFFFAOYSA-N 0.000 description 3
- DMLRSJNZORFCBD-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-5-amine Chemical compound O1CCOC2=C1C=CC=C2N DMLRSJNZORFCBD-UHFFFAOYSA-N 0.000 description 3
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 3
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 3
- RVJYYSODCHQATJ-UHFFFAOYSA-N 3,8-dimethoxynaphthalene-2-carboxylic acid Chemical compound C1=CC(OC)=C2C=C(C(O)=O)C(OC)=CC2=C1 RVJYYSODCHQATJ-UHFFFAOYSA-N 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910052776 Thorium Inorganic materials 0.000 description 3
- PBOYJAITSSDOFN-UHFFFAOYSA-N [1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CN)CC1 PBOYJAITSSDOFN-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- RBUFUWIWCCOVOS-UHFFFAOYSA-N 1,6-dimethoxynaphthalene Chemical compound COC1=CC=CC2=CC(OC)=CC=C21 RBUFUWIWCCOVOS-UHFFFAOYSA-N 0.000 description 2
- JGHAHEUJMFFMQA-UHFFFAOYSA-N 1-(2-chlorophenyl)piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1C1=CC=CC=C1Cl JGHAHEUJMFFMQA-UHFFFAOYSA-N 0.000 description 2
- ZJYUUAQHPGQMQO-UHFFFAOYSA-N 1-phenylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1C1=CC=CC=C1 ZJYUUAQHPGQMQO-UHFFFAOYSA-N 0.000 description 2
- NLONAIMSLGVOEX-UHFFFAOYSA-N 1-phenylpyridin-1-ium-4-carboxamide;chloride Chemical compound [Cl-].C1=CC(C(=O)N)=CC=[N+]1C1=CC=CC=C1 NLONAIMSLGVOEX-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- DZJPDDVDKXHRLF-UHFFFAOYSA-N 2-hydroxy-6-methoxybenzaldehyde Chemical compound COC1=CC=CC(O)=C1C=O DZJPDDVDKXHRLF-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 2
- FWQWIQPLYSRSDQ-UHFFFAOYSA-N 5-methoxy-2h-chromene-3-carboxylic acid Chemical compound O1CC(C(O)=O)=CC2=C1C=CC=C2OC FWQWIQPLYSRSDQ-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 229910000103 lithium hydride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- OLSUMCUJAFRBLY-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-(1-pyridin-2-ylpiperidin-4-yl)methanamine;dihydrochloride Chemical compound Cl.Cl.C1OC2=CC=CC=C2OC1CNCC(CC1)CCN1C1=CC=CC=N1 OLSUMCUJAFRBLY-UHFFFAOYSA-N 0.000 description 2
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- YNBDZQRMEDQOQM-UHFFFAOYSA-N oxan-2-ylmethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1OCCCC1 YNBDZQRMEDQOQM-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
- 229960001999 phentolamine Drugs 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- KOBWFEXXYDXJGO-UHFFFAOYSA-N (1-phenylpiperidin-4-yl)methanamine Chemical compound C1CC(CN)CCN1C1=CC=CC=C1 KOBWFEXXYDXJGO-UHFFFAOYSA-N 0.000 description 1
- VUCQVGAIMMSEGJ-UHFFFAOYSA-N (1-pyrazin-2-ylpiperidin-4-yl)methanamine Chemical compound C1CC(CN)CCN1C1=CN=CC=N1 VUCQVGAIMMSEGJ-UHFFFAOYSA-N 0.000 description 1
- ZADAPLCYCBLHPU-UHFFFAOYSA-N (1-pyrimidin-2-ylpiperidin-4-yl)methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC=N1 ZADAPLCYCBLHPU-UHFFFAOYSA-N 0.000 description 1
- BTMPTBVFEBPRFL-UHFFFAOYSA-N (1-pyrimidin-2-ylpiperidin-4-yl)methanamine;dihydrochloride Chemical class Cl.Cl.C1CC(CN)CCN1C1=NC=CC=N1 BTMPTBVFEBPRFL-UHFFFAOYSA-N 0.000 description 1
- QKEUUKJFWUCBKR-UHFFFAOYSA-N (5-methoxy-2,3-dihydro-1,4-benzodioxin-3-yl)methanol Chemical compound O1CC(CO)OC2=C1C=CC=C2OC QKEUUKJFWUCBKR-UHFFFAOYSA-N 0.000 description 1
- LLTFQWFWQMCIOW-UHFFFAOYSA-N (5-methoxy-3,4-dihydro-2h-chromen-3-yl)methanol Chemical compound O1CC(CO)CC2=C1C=CC=C2OC LLTFQWFWQMCIOW-UHFFFAOYSA-N 0.000 description 1
- LWIHHPCCKDJVTO-UHFFFAOYSA-N (5-methoxy-3,4-dihydro-2h-chromen-3-yl)methyl 4-methylbenzenesulfonate Chemical compound C1C=2C(OC)=CC=CC=2OCC1COS(=O)(=O)C1=CC=C(C)C=C1 LWIHHPCCKDJVTO-UHFFFAOYSA-N 0.000 description 1
- ABBGCRDSJWFWNW-UHFFFAOYSA-N (8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate Chemical compound C1C=2C(OC)=CC=CC=2CCC1COS(=O)(=O)C1=CC=C(C)C=C1 ABBGCRDSJWFWNW-UHFFFAOYSA-N 0.000 description 1
- IDFPQEHZYBXIFO-GFCCVEGCSA-N (R)-(4-fluoro-2-propylphenyl)-(1H-imidazol-2-yl)methanol Chemical compound CCCc1cc(F)ccc1[C@@H](O)c1ncc[nH]1 IDFPQEHZYBXIFO-GFCCVEGCSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical group [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- ZPHITLFRKHZKBG-UHFFFAOYSA-N 1-(1-ethoxyethoxy)-3-methoxybenzene Chemical compound CCOC(C)OC1=CC=CC(OC)=C1 ZPHITLFRKHZKBG-UHFFFAOYSA-N 0.000 description 1
- QFLRQYIAZGJACR-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidine Chemical compound C1CCCCN1C1=CC=CC2=C1OCCO2 QFLRQYIAZGJACR-UHFFFAOYSA-N 0.000 description 1
- IFJZGMAUNGUYTH-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)pyridin-1-ium-4-carboxamide;chloride Chemical compound [Cl-].C1=CC(C(=O)N)=CC=[N+]1C1=CC=CC2=C1OCCO2 IFJZGMAUNGUYTH-UHFFFAOYSA-N 0.000 description 1
- UKYNNARYKRJBNN-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperidine-4-carboxamide Chemical compound COC1=CC=CC=C1N1CCC(C(N)=O)CC1 UKYNNARYKRJBNN-UHFFFAOYSA-N 0.000 description 1
- MCBJPVNEVNYTJZ-UHFFFAOYSA-N 1-(4-methoxyphenyl)pyridin-1-ium-4-carboxamide;chloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[N+]1=CC=C(C(N)=O)C=C1 MCBJPVNEVNYTJZ-UHFFFAOYSA-N 0.000 description 1
- CSWPZFOPVQMWKT-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)piperidin-4-yl]-n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)methanamine Chemical compound ClC1=CC=CC=C1N1CCC(CNCC2OC3=CC=CC=C3OC2)CC1 CSWPZFOPVQMWKT-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- KTLYWOJAAZDRCJ-UHFFFAOYSA-N 1-n'-[3-(trifluoromethyl)pyridin-2-yl]ethane-1,1-diamine Chemical compound CC(N)NC1=NC=CC=C1C(F)(F)F KTLYWOJAAZDRCJ-UHFFFAOYSA-N 0.000 description 1
- BSMFKJKMQXMVFX-UHFFFAOYSA-N 1-n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-n'-[3-(trifluoromethyl)pyridin-2-yl]ethane-1,1-diamine Chemical compound C1OC2=CC=CC=C2OC1CNC(C)NC1=NC=CC=C1C(F)(F)F BSMFKJKMQXMVFX-UHFFFAOYSA-N 0.000 description 1
- GEZGAZKEOUKLBR-UHFFFAOYSA-N 1-phenylpyrrole Chemical compound C1=CC=CN1C1=CC=CC=C1 GEZGAZKEOUKLBR-UHFFFAOYSA-N 0.000 description 1
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 1
- GWQOQQVKVOOHTI-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethanol Chemical compound C1=CC=C2OC(CO)COC2=C1 GWQOQQVKVOOHTI-UHFFFAOYSA-N 0.000 description 1
- UHHZGSLXPQGPJL-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-7-amine Chemical compound NC1=CC=CC2=C1OCC2 UHHZGSLXPQGPJL-UHFFFAOYSA-N 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- LXQOQPGNCGEELI-UHFFFAOYSA-N 2,4-dinitroaniline Chemical group NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O LXQOQPGNCGEELI-UHFFFAOYSA-N 0.000 description 1
- SDLPKZAWPTWSEV-UHFFFAOYSA-N 2,4-dinitrofuran Chemical compound [O-][N+](=O)c1coc(c1)[N+]([O-])=O SDLPKZAWPTWSEV-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- VKJCJJYNVIYVQR-UHFFFAOYSA-N 2-(3-bromopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCBr)C(=O)C2=C1 VKJCJJYNVIYVQR-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- AYPKYQSHFKQVDL-UHFFFAOYSA-N 3-(chloromethyl)-2,3-dihydro-1,4-benzodioxine Chemical compound C1=CC=C2OC(CCl)COC2=C1 AYPKYQSHFKQVDL-UHFFFAOYSA-N 0.000 description 1
- DRMOSUOUZKVUBE-UHFFFAOYSA-N 3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-ol Chemical compound C1=CC(O)=C2OC(CO)COC2=C1 DRMOSUOUZKVUBE-UHFFFAOYSA-N 0.000 description 1
- JFGQHAHJWJBOPD-UHFFFAOYSA-N 3-hydroxy-n-phenylnaphthalene-2-carboxamide Chemical compound OC1=CC2=CC=CC=C2C=C1C(=O)NC1=CC=CC=C1 JFGQHAHJWJBOPD-UHFFFAOYSA-N 0.000 description 1
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 1
- XCJAEPPTPJDXQG-UHFFFAOYSA-N 4-[2-(5-methoxy-2,3-dihydro-1,4-benzodioxin-3-yl)ethyl]benzenesulfonic acid Chemical compound COC1=CC=CC2=C1OC(CO2)CCC3=CC=C(C=C3)S(=O)(=O)O XCJAEPPTPJDXQG-UHFFFAOYSA-N 0.000 description 1
- WWOBYPKUYODHDG-UHFFFAOYSA-N 4-chlorocatechol Chemical compound OC1=CC=C(Cl)C=C1O WWOBYPKUYODHDG-UHFFFAOYSA-N 0.000 description 1
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- FUGKCSRLAQKUHG-UHFFFAOYSA-N 5-chloro-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Cl)C=C1C=O FUGKCSRLAQKUHG-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- DLMVOXMRGJFYOC-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1,4-benzodioxine Chemical compound O1CCOC2=C1C=CC=C2OC DLMVOXMRGJFYOC-UHFFFAOYSA-N 0.000 description 1
- MSRYWCWCCLEHDI-UHFFFAOYSA-N 6,7-dichloro-2,3-dihydro-1,4-benzodioxine Chemical compound O1CCOC2=C1C=C(Cl)C(Cl)=C2 MSRYWCWCCLEHDI-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- IAMGLKFTCUZWQO-UHFFFAOYSA-N 6-chloro-2,3-dihydro-1,4-benzodioxine Chemical compound O1CCOC2=CC(Cl)=CC=C21 IAMGLKFTCUZWQO-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- ZAPYZFMJCLMKMW-UHFFFAOYSA-N CC1=C(C=C(C=C1Cl)S(=O)(=O)O)CC2COC3=C(O2)C=C(C=C3)Cl Chemical compound CC1=C(C=C(C=C1Cl)S(=O)(=O)O)CC2COC3=C(O2)C=C(C=C3)Cl ZAPYZFMJCLMKMW-UHFFFAOYSA-N 0.000 description 1
- 101100127891 Caenorhabditis elegans let-4 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- LWTYNKZHAZYGCQ-UHFFFAOYSA-N N-(2,3-dihydrobenzo[h][1,4]benzodioxin-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCC(CNCC2OC3=C4C=CC=CC4=CC=C3OC2)CC1 LWTYNKZHAZYGCQ-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- NOQXXYIGRPAZJC-SECBINFHSA-N [(2r)-oxiran-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@@H]1OC1 NOQXXYIGRPAZJC-SECBINFHSA-N 0.000 description 1
- OTGAYUCEDFKLHW-CYBMUJFWSA-N [(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@@H]1OC2=CC=CC=C2OC1 OTGAYUCEDFKLHW-CYBMUJFWSA-N 0.000 description 1
- GWQOQQVKVOOHTI-ZETCQYMHSA-N [(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methanol Chemical compound C1=CC=C2O[C@@H](CO)COC2=C1 GWQOQQVKVOOHTI-ZETCQYMHSA-N 0.000 description 1
- OTGAYUCEDFKLHW-ZDUSSCGKSA-N [(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@H]1OC2=CC=CC=C2OC1 OTGAYUCEDFKLHW-ZDUSSCGKSA-N 0.000 description 1
- VNNMNJNIUXMGPP-UHFFFAOYSA-N [1-(2,3-dihydro-1-benzofuran-7-yl)piperidin-4-yl]methanamine Chemical compound C1CC(CN)CCN1C1=CC=CC2=C1OCC2 VNNMNJNIUXMGPP-UHFFFAOYSA-N 0.000 description 1
- SQVYMEPYBSQWKK-UHFFFAOYSA-N [1-(3-chloropyridin-2-yl)piperidin-4-yl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC=C1Cl SQVYMEPYBSQWKK-UHFFFAOYSA-N 0.000 description 1
- JUPQXBACXUJVHI-UHFFFAOYSA-N [1-(3-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC(N2CCC(CN)CC2)=C1 JUPQXBACXUJVHI-UHFFFAOYSA-N 0.000 description 1
- SKXFUBHZYBNOPT-UHFFFAOYSA-K [Al](Br)(Br)Br.[Li] Chemical compound [Al](Br)(Br)Br.[Li] SKXFUBHZYBNOPT-UHFFFAOYSA-K 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 229960002944 cyclofenil Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004310 dioxan-2-yl group Chemical group [H]C1([H])OC([H])([H])C([H])(*)OC1([H])[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- IYWCBYFJFZCCGV-UHFFFAOYSA-N formamide;hydrate Chemical compound O.NC=O IYWCBYFJFZCCGV-UHFFFAOYSA-N 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 125000006377 halopyridyl group Chemical group 0.000 description 1
- VJKYNWPQVZHJAR-UHFFFAOYSA-H hexasodium trisulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VJKYNWPQVZHJAR-UHFFFAOYSA-H 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-O hydron;pyrimidine Chemical compound C1=CN=C[NH+]=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-O 0.000 description 1
- HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
- 229950001476 idazoxan Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- QENXEYHBJODKRK-UHFFFAOYSA-N methanamine hydrate hydrochloride Chemical compound O.Cl.CN QENXEYHBJODKRK-UHFFFAOYSA-N 0.000 description 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- AJBXZIWSQRLNPO-UHFFFAOYSA-N n'-(2-methoxyphenyl)propane-1,3-diamine Chemical compound COC1=CC=CC=C1NCCCN AJBXZIWSQRLNPO-UHFFFAOYSA-N 0.000 description 1
- XYBADQIMVGSILK-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNCC2OC3=CC=CC=C3OC2)CC1 XYBADQIMVGSILK-UHFFFAOYSA-N 0.000 description 1
- VHRGBJGDFDUOBN-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-[1-(4-methoxyphenyl)piperidin-4-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1N1CCC(CNCC2OC3=CC=CC=C3OC2)CC1 VHRGBJGDFDUOBN-UHFFFAOYSA-N 0.000 description 1
- GYJMXCUAHCRMAS-UHFFFAOYSA-N n-(2-methoxyphenyl)piperidine-4-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C1CCNCC1 GYJMXCUAHCRMAS-UHFFFAOYSA-N 0.000 description 1
- SJDIPKJXGRZDGT-UHFFFAOYSA-N n-[(5-fluoro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCC(CNCC2OC3=CC=CC(F)=C3OC2)CC1 SJDIPKJXGRZDGT-UHFFFAOYSA-N 0.000 description 1
- CRJAXYUEXJJYKH-UHFFFAOYSA-N n-[(5-methoxy-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]-n'-(2-methoxyphenyl)propane-1,3-diamine Chemical compound COC1=CC=CC=C1NCCCNCC1OC2=C(OC)C=CC=C2OC1 CRJAXYUEXJJYKH-UHFFFAOYSA-N 0.000 description 1
- PRQCIQWKKXWYSY-UHFFFAOYSA-N n-[(8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]-1-(1-pyrimidin-2-ylpiperidin-4-yl)methanamine Chemical compound C1C=2C(OC)=CC=CC=2CCC1CNCC(CC1)CCN1C1=NC=CC=N1 PRQCIQWKKXWYSY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- XYBADQIMVGSILK-GOSISDBHSA-N n-[[(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine Chemical compound COC1=CC=CC=C1N1CCC(CNC[C@H]2OC3=CC=CC=C3OC2)CC1 XYBADQIMVGSILK-GOSISDBHSA-N 0.000 description 1
- FZZQNEVOYIYFPF-UHFFFAOYSA-N naphthalene-1,6-diol Chemical compound OC1=CC=CC2=CC(O)=CC=C21 FZZQNEVOYIYFPF-UHFFFAOYSA-N 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940096717 pamine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- REJGOFYVRVIODZ-UHFFFAOYSA-N phosphanium;chloride Chemical compound P.Cl REJGOFYVRVIODZ-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 式I: [式中、 Aはメチレン又は−O−であり、 Bはメチレン又は−O−であり、 gは、0,1,2,3又は4であり、 R1は、a)ハロゲン原子、b)場合により1個以上のハロゲン原子により置 換された1〜3個の炭素原子を有するアルキル基、c)場合により1個以上のハ ロゲン原子により置換された1〜3個の炭素原子を有するアルコキシ基、d)場 合により1個以上のハロゲン原子により置換された1〜3個の炭素原子を有する アルキルチオ基、e)ヒドロキシ、f)1〜3個の炭素原子を有するアシルオキ シ基、g)ヒドロキシメチル、h)シアノ、i)1〜6個の炭素原子を有するア ルカノイル基、j)2〜6個の炭素原子を有するアルコキシカルボニル基、k) カルバモイル基又はカルバモイルメチル基、これらはそれぞれ場合によりそれぞ れ1〜3個の炭素原子を有する1又は2個のアルキル 基によりN−置換されている、l)スルファモイル又はスルファモイルメチル基 、これらはそれぞれ1〜3個の炭素原子を有する1又は2個のアルキル基により N−置換されている、m)場合によりそれぞれ1〜3個の炭素原子を有する1又 は2個の炭素原子を有するアルキル基により置換されたアミノ基;又は2個の隣 接したR1基はそれらが結合した炭素原子とと一緒に縮合したベンズ環を形成し 、その際R1で表される置換基は、gが2,3又は4である場合には、同じか又 は異なっている、 R2はH、1〜3個の炭素原子を有するアルキル基、又は1〜3個の炭素原子 を有するアルコキシ基であり、 R3及びR4は、同じか又は異なっており、H又は1は1〜3個の炭素原子を有 するアルキル基であり、 Uは、場合により1〜3個の炭素原子を有する1個以上のアルキル基により置 換された1〜3個の炭素原子を有するアルキレン鎖であり、 Qは、式IIa,IIb又はIIc: (上記式中、 Vは、単結合、又は場合によりそれぞれ1〜3個の炭素原子を有する1個以上 のアルキル基により置換されたそれぞれ1〜3個の炭素原子を有するアルキレン 鎖であり、¥ Xは、0〜2個の個の炭素原子を有するアルキレン鎖及びX′は、1〜4個の 炭素原子を有するアルキレン鎖であり、但しXとX′中の炭素原子の総計は3又 は4になり、 R5は、H又は1〜3個の炭素原子を有するアルキル基である)で示される2 価の基を表し、 かつ Tは、場合により1個以上のN原子を有しかつ場合によりハロゲン原子、1〜 3個の炭素原子を有するアルキル基、1〜3個の炭素原子を有するアルコキシ基 、又は多ハロゲン化されたアルキル基から選択される1個以上の置換基により置 換された芳香族基を表すか、又はTはベンゾ[b]フラニル又はベンゾジオキサ ニルを表し、但しAが−O−、Bが−O−又はCH2、gが0,1又は2であり 、R1がハロゲン原子、C1-3アルキル、ヒドロキシ、C1-3アルコキシ、シアノ 、カルボキシ、C2-6アルコキシカルボニル、アミノ、アミノカルボニル、C1-6 アルキルカルボニルアミノ、又はモノ−又はジ−(C1-3アルキル)−アミノ、 R2がH又はC1-3アルキル、R3とR4は両者 ともH、UがC1-3アルキレン及びQが式IIa又はIIcである場合には、Tはピ リジン−2−イル、1,3,5−トリアジン−2−イル又は1,3,4−トリア ジン−2−イルである]で示される化合物及びその製薬学的に認容される塩。 2.Aが−O−である、請求項1記載の式Iの化合物。 3.Bが−O−である、請求項1から2までのいずれか1項記載の式Iの化合 物。 4.gが0,1又は2である、請求項1から3までのいずれか1項記載の式I の化合物。 5.R1がハロゲン、1〜3個の炭素原子を有するアルキル基、1〜3個の炭 素原子を有するアルコキシ基、ヒドロキシを表し、又は2つの隣接したR1は、 それらが結合された炭素原子と一緒に縮合したベンズ環を形成する、請求項1か ら4までのいずれか1項記載の式Iの化合物。 6.R1がメトキシ、フルオロ、クロロ、ヒドロキシを表し、又は2つの隣接 したR1が、それらが結合された炭素原子と一緒に縮合したベンズ環を形成する 、請求項1から5までのいずれか1項記載の式Iの化合物。 7.R2がH又は1〜3個の炭素原子を有するアルキル基である、請求項1か ら6までのいずれか1項記載の式Iの化合物。 8. R3及びR4が、同じか又は異なっており、H又はメチルである、請求項 1から7までのいずれか1項記載の式Iの化合物。 9.Tがピリジル、ピリミジル、ピラジニル、フェニル、ベンゾフラニル、1 ,4−ベンゾジオキサニル又はキナゾリニルであり、これらは全て場合によりメ トキシ、トリフルオロメチル、又はハロゲン原子により置換されていてもよい、 請求項1から8までのいずれか1項記載の式Iの化合物。 10.Tが2−ピリジル、2−ピリミジル、2−ピラジニル、フェニル、2,3 −ジヒドロベンゾ[b]フラン−7−イル、1,4−ベンゾジオキサン−5−イ ル、又は4−キナゾリニルであり、これらは全て場合によりメトキシ、トリフル オロメチル、又はハロゲン原子により置換されていてもよい、請求項1から8ま でのいずれか1項記載の式Iの化合物。 11.R5がH又はメチルである、請求項1から10までのいずれか1項記載の 式Iの化合物。 12. N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(ピラジン −2−イル)ピペリド−4−イル]メチルアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(2−メト キシフェニルル)ピペリド−4−イル]メチルアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(3−クロ ルピリド−4−イル)ピペリド−4−イルメチル]メチルアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(キナゾリ ン−4−イル)ピペリド−4−イル]メチルアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(ピペリド −4−イル)ピペリド−4−イル]メチルアミン; N−(8−メトキシ−1,4−ベンゾジオキサン−2−イルメチル)−1−[ 1−(2−メトキシフェニル)ピペリド−4−イル]メチルアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−N′−[3−(トリフ ルオロメチル)−2−ピリジル]エタンアミン; N−(8−メトキシ−1,2,3,4−テトラヒドロナフチ−2−イルメチル )−1−[1−ピリミジン−2−イル]メチルアミン; 7−{N−[1−(ピリミジン−2−イル)ピペリド−4−イルメチル]アミ ノメチル}−5,6,7,8−テトラヒドロナフト−2−オール; N−(5−メトキシ−3,4−ジヒドロ−2H−1−ベンゾピラン−3−イル メチル)−1−[1−(ピリミジン−2−イル)ピペリド−4−イル]メチルア ミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−(1−フェニルピ ペリド−4−イル)メチルアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(1,4− ベンゾジオキサン−5−イル)ピペリド−4−イル]メチルアミン; 1−[1−(1,4−ベンゾジオキサン−2−イルメチル)ピペリド−4−イ ル]−N−(2−メトキシフェニル)メチルジアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(4−メト キシフェニル)ピペリド−4−イル]メチルアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(3−メト キシフェニル)ピペリド−4−イル]メチルアミン; N−(6,7−ジクロロ−1,4−ベンゾジオキサン−2−イルメチル)−1 −[1−(2−メトキシフェニル)ピペリド−4−イル]メチルアミン; N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−(2−クロ ロフェニル)ピペリド−4−イル]メチルアミン; N−(5−フルオロ−1,4−ベンゾジオキサン−2−イルメチル)−1−[ 1−(2−メトキシフェニル)ピペリド−4−イル]メチルアミン; N−(8−フルオロ−1,4−ベンゾジオキサン− 2−イルメチル)−1−[1−(2−メトキシフェニル)ピペリド−4−イル] メチルアミン; 1−[1−(2−メトキシフェニル)ピペリド−4−イル]−N−(ナフト[ 1,2−b]ジオキサン−2−イルメチル)メチルアミン; 1−[1−(2,3−ジヒドロベンゾ[b]フラン−7−イル)ピペリド−4 −イル]−N−(8−メトキシ−1,4−ベンゾジオキサン−2−イルメチル) メチルアミン; N−(6−クロロ−1,4−ベンゾジオキサン−2−イルメチル)−1−[1 −(2−メトキシフェニル)ピペリド−4−イル]メチルアミン; N−(7−クロロ−1,4−ベンゾジオキサン−2−イルメチル)−1−[1 −(2−メトキシフェニル)ピペリド−4−イル]メチルアミン; N−(8−ヒドロキシ−1,4−ベンゾジオキサン−2−イルメチル)−1− [1−(2−メトキシフェニル)ピペリド−4−イル]メチルアミン; 及びそれらの製薬学的に認容される塩である、請求項1項記載の式Iの化合物。 13. (S)−(−)−N−(1,4−ベンゾジオキサン−2−イルメチル) −1−[1−(2−メトキシフェニル)ピペリド−4−イル]メチルアミン; (R)−(+)−N−(1,4−ベンゾジオキサン−2−イルメチル)−1− [1−(2−メトキシフェ ニル)ピペリド−4−イル]メチルアミン; (−)−N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−( ピリド−2−イル)ピペリド−4−イル]メチルアミン・二塩差塩; (+)−N−(1,4−ベンゾジオキサン−2−イルメチル)−1−[1−( ピリド−2−イル)ピペリド−4−イル]メチルアミン・二塩差塩である、請求 項1記載の化合物。 14.治療学的に有効な量の、請求項1記載の式Iの化合物を、製薬学的に認容 される希釈剤又は賦形剤と一緒に含有する、製薬学的組成物。 15.請求項1から13までのいずれか1項記載の式Iの化合物の治療学的に有 効量をそれが必要である患者に投与することを特徴とする、鬱病、不安、精神病 、パーキンソン症候群、又は肥満症を治療する方法。 16.精神分裂病を治療する、請求項16記載の方法。 17.不安を治療するための、請求項15記載の方法。 18.請求項1から13までのいずれか1項記載の式Iの化合物の医薬としての 使用。 19.請求項1から13までのいずれか1項記載の式Iの化合物の、鬱病、不安 、精神病、晩発性異常動揺病、パーキンソン症候群、又は肥満症を治療するため の医薬としての使用。 20.請求項1から13までのいずれか1項記載の式Iの化合物の、鬱病、不安 、精神病、晩発性異常動揺病、パーキンソン症候群、又は肥満症を治療するため の医薬の製造にける使用。 21.請求項1記載の式Iの化合物を製造する方法において、 a)式III: の化合物を式IV: と反応させ、引き続き中間体のイミンを還元剤と反応させて、Qが式IIaの基で あって、該式中R5がH及びVが(CH2)n+1であり、この場合n=0,1又は 2である式Iの化合物を得る、 b)式IIIの化合物を式V: [式中、Yは離脱基である]の化合物と反応させて、 Qが式IIaの基であって、該式中R5がH及びVが(CH2)n+1であり、この 場合n=0,1又は2である式Iの化合物を得る、 c)式VI: の化合物を式VII: [式中、Zは離脱基である]の化合物と反応させて、 Qが式IIaの基であって、該式中R5がH及びVが(CH2)n+1であり、この 場合n=0,1又は2である式Iの化合物を得る、 d)式VI:の化合物を式VIII: の化合物と反応させ、引き続き中間体のイミンを還元して、Uがメチレンであり 、Qが式IIaの基であって、該式中R5がH及びVが(CH2)n+1であり、こ の場合n=0,1又は2である式Iの化合物を得る、又は e)式XLII: の化合物をハロゲン化芳香族化合物と反応させて、Qが式IIcである化合物を得 る ことを特徴とする、式Iの化合物の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9318431.5 | 1993-09-06 | ||
GB939318431A GB9318431D0 (en) | 1993-09-06 | 1993-09-06 | Therapeutic agents |
PCT/EP1994/002904 WO1995007274A1 (en) | 1993-09-06 | 1994-09-01 | Bicyclic aromatic compounds as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09502431A true JPH09502431A (ja) | 1997-03-11 |
Family
ID=10741568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7508440A Ceased JPH09502431A (ja) | 1993-09-06 | 1994-09-01 | 治療薬剤としての二環式芳香族化合物 |
Country Status (31)
Country | Link |
---|---|
US (1) | US5767116A (ja) |
EP (1) | EP0717739B1 (ja) |
JP (1) | JPH09502431A (ja) |
KR (1) | KR100325964B1 (ja) |
CN (1) | CN1052723C (ja) |
AT (1) | ATE191214T1 (ja) |
AU (1) | AU689802B2 (ja) |
BG (1) | BG63272B1 (ja) |
BR (1) | BR9407413A (ja) |
CA (1) | CA2170056A1 (ja) |
CZ (1) | CZ61496A3 (ja) |
DE (1) | DE69423767T2 (ja) |
DK (1) | DK0717739T3 (ja) |
ES (1) | ES2144528T3 (ja) |
FI (1) | FI961016A0 (ja) |
GB (1) | GB9318431D0 (ja) |
GR (1) | GR3033575T3 (ja) |
HU (1) | HUT75875A (ja) |
IL (1) | IL110844A (ja) |
NO (1) | NO308536B1 (ja) |
NZ (1) | NZ273581A (ja) |
PL (1) | PL178270B1 (ja) |
PT (1) | PT717739E (ja) |
RO (1) | RO116811B1 (ja) |
RU (1) | RU2136680C1 (ja) |
SI (1) | SI9420058B (ja) |
SK (1) | SK27196A3 (ja) |
TW (1) | TW311137B (ja) |
UA (1) | UA41952C2 (ja) |
WO (1) | WO1995007274A1 (ja) |
ZA (1) | ZA946798B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006503040A (ja) * | 2002-09-12 | 2006-01-26 | ワイス | 抗うつ剤としての複素環融合ベンゾジオキサンから成るシクロアルキルアミン誘導体 |
JP2006507250A (ja) * | 2002-09-12 | 2006-03-02 | ワイス | 抗うつ作用を有するヘテロ環融合ベンゾジオキサンのアリルピペラジン誘導体 |
JP2006510594A (ja) * | 2002-09-12 | 2006-03-30 | ワイス | 抗うつ作用を有する複素環縮合ベンゾジオキサンのピペリジン誘導体 |
JP2006510595A (ja) * | 2002-09-12 | 2006-03-30 | ワイス | 複素環縮合ベンゾジオキサンメチルアミンの抗うつ作用性インドールアルキル誘導体 |
JP2006290890A (ja) * | 2005-04-08 | 2006-10-26 | Lab Servier | ピペラジン化合物、その製造方法およびそれを含有する医薬組成物 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
FR2738823B1 (fr) * | 1995-09-15 | 1997-10-31 | Synthelabo | Derives de 3-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)-3,4-dihydroquinolein-2(1h)-one,leur preparation et leur application en therapeutique |
GB9526495D0 (en) * | 1995-12-23 | 1996-02-28 | Knoll Ag | Therapeutic agents |
DE19624154A1 (de) | 1996-06-18 | 1998-01-08 | Hoechst Ag | Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung |
GB9627006D0 (en) * | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
GB9627005D0 (en) | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
FR2760014B1 (fr) * | 1997-02-27 | 1999-04-09 | Adir | Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9704948D0 (en) | 1997-03-11 | 1997-04-30 | Knoll Ag | Therapeutic agents |
FR2761358B1 (fr) * | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6077850A (en) | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
GB9811879D0 (en) * | 1998-06-03 | 1998-07-29 | Knoll Ag | Therapeutic agents |
FR2780057B1 (fr) * | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR2782515B1 (fr) * | 1998-08-21 | 2000-09-22 | Adir | NOUVEAUX DERIVES DE L'INDANE-1-Ol, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
GB9915616D0 (en) * | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
GB0007376D0 (en) * | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
US6458804B1 (en) * | 2001-01-26 | 2002-10-01 | R.T. Alamo Venturesi, Llc | Methods for the treatment of central nervous system disorders in certain patient groups |
US6656951B2 (en) | 2001-04-24 | 2003-12-02 | Wyeth | 8-aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benzodioxan as 5-HT1A antagonists |
US6656950B2 (en) | 2001-04-25 | 2003-12-02 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine |
US6656947B2 (en) | 2001-04-26 | 2003-12-02 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline |
DE10120619A1 (de) * | 2001-04-26 | 2002-10-31 | Merck Patent Gmbh | 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman |
GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
WO2003031439A1 (en) * | 2001-10-05 | 2003-04-17 | Wyeth | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole |
PT1888548E (pt) | 2005-05-26 | 2012-10-30 | Neuron Systems Inc | Derivado de quinolina para o tratamento de doenças da retina |
TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物 |
AU2017287919A1 (en) | 2016-06-29 | 2019-01-17 | Orion Corporation | Benzodioxane derivatives and their pharmaceutical use |
WO2020033344A1 (en) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス, インコーポレイテッド | 多形化合物およびその使用 |
CA3175856A1 (en) | 2020-05-13 | 2021-11-18 | Todd Brady | Pharmaceutical formulations and uses thereof |
CN117580569A (zh) * | 2021-07-02 | 2024-02-20 | 奥尔德拉医疗公司 | 杂环型醛捕获化合物和其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684739A (en) * | 1980-12-15 | 1987-08-04 | Mitsubishi Chemical Industries Limited | Alkylenedioxybenzene derivatives and acid addition salts thereof |
JPS58154574A (ja) * | 1982-03-09 | 1983-09-14 | Mitsubishi Chem Ind Ltd | アルキレンジオキシベンゼン誘導体およびその酸付加塩 |
US4569933A (en) * | 1984-04-13 | 1986-02-11 | Cornu Pierre Jean | Antihypertensive substituted derivatives of 2,5-diamino 1,4-diazole |
CA1260474A (en) * | 1984-12-03 | 1989-09-26 | Raymond A. Stokbroekx | Benzoxazol- and benzothiazolamine derivatives |
US4749702A (en) * | 1985-04-15 | 1988-06-07 | Janssen Pharmaceutica N. V. | Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines |
DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
FR2658823B1 (fr) * | 1990-02-27 | 1992-04-30 | Adir | Nouveaux derives d'aminomethylpiperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent . |
US5182292A (en) * | 1991-06-21 | 1993-01-26 | American Home Products Corporation | Psychotropic piperidinylmethyl benzodioxans |
FR2681325B1 (fr) * | 1991-09-16 | 1993-12-17 | Fabre Medicament Pierre | Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique. |
SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
-
1993
- 1993-09-06 GB GB939318431A patent/GB9318431D0/en active Pending
-
1994
- 1994-09-01 PL PL94313347A patent/PL178270B1/pl unknown
- 1994-09-01 PT PT94927531T patent/PT717739E/pt unknown
- 1994-09-01 CN CN94193808A patent/CN1052723C/zh not_active Expired - Fee Related
- 1994-09-01 DE DE69423767T patent/DE69423767T2/de not_active Expired - Fee Related
- 1994-09-01 EP EP94927531A patent/EP0717739B1/en not_active Expired - Lifetime
- 1994-09-01 DK DK94927531T patent/DK0717739T3/da active
- 1994-09-01 RO RO96-00406A patent/RO116811B1/ro unknown
- 1994-09-01 BR BR9407413A patent/BR9407413A/pt not_active Application Discontinuation
- 1994-09-01 UA UA96041333A patent/UA41952C2/uk unknown
- 1994-09-01 CZ CZ96614A patent/CZ61496A3/cs unknown
- 1994-09-01 JP JP7508440A patent/JPH09502431A/ja not_active Ceased
- 1994-09-01 HU HU9600552A patent/HUT75875A/hu unknown
- 1994-09-01 ES ES94927531T patent/ES2144528T3/es not_active Expired - Lifetime
- 1994-09-01 KR KR1019960701111A patent/KR100325964B1/ko not_active IP Right Cessation
- 1994-09-01 AU AU76928/94A patent/AU689802B2/en not_active Ceased
- 1994-09-01 US US08/605,130 patent/US5767116A/en not_active Expired - Lifetime
- 1994-09-01 RU RU96113203A patent/RU2136680C1/ru active
- 1994-09-01 AT AT94927531T patent/ATE191214T1/de not_active IP Right Cessation
- 1994-09-01 CA CA002170056A patent/CA2170056A1/en not_active Abandoned
- 1994-09-01 SK SK271-96A patent/SK27196A3/sk unknown
- 1994-09-01 SI SI9420058A patent/SI9420058B/sl unknown
- 1994-09-01 WO PCT/EP1994/002904 patent/WO1995007274A1/en not_active Application Discontinuation
- 1994-09-01 NZ NZ273581A patent/NZ273581A/en unknown
- 1994-09-02 IL IL11084494A patent/IL110844A/xx not_active IP Right Cessation
- 1994-09-05 ZA ZA946798A patent/ZA946798B/xx unknown
-
1995
- 1995-03-04 TW TW084102088A patent/TW311137B/zh active
-
1996
- 1996-02-29 BG BG100388A patent/BG63272B1/bg unknown
- 1996-03-05 NO NO960888A patent/NO308536B1/no not_active IP Right Cessation
- 1996-03-05 FI FI961016A patent/FI961016A0/fi unknown
-
2000
- 2000-05-31 GR GR20000401270T patent/GR3033575T3/el not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006503040A (ja) * | 2002-09-12 | 2006-01-26 | ワイス | 抗うつ剤としての複素環融合ベンゾジオキサンから成るシクロアルキルアミン誘導体 |
JP2006507250A (ja) * | 2002-09-12 | 2006-03-02 | ワイス | 抗うつ作用を有するヘテロ環融合ベンゾジオキサンのアリルピペラジン誘導体 |
JP2006510594A (ja) * | 2002-09-12 | 2006-03-30 | ワイス | 抗うつ作用を有する複素環縮合ベンゾジオキサンのピペリジン誘導体 |
JP2006510595A (ja) * | 2002-09-12 | 2006-03-30 | ワイス | 複素環縮合ベンゾジオキサンメチルアミンの抗うつ作用性インドールアルキル誘導体 |
JP2006290890A (ja) * | 2005-04-08 | 2006-10-26 | Lab Servier | ピペラジン化合物、その製造方法およびそれを含有する医薬組成物 |
JP4607809B2 (ja) * | 2005-04-08 | 2011-01-05 | レ ラボラトワール セルヴィエ | ピペラジン化合物、その製造方法およびそれを含有する医薬組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09502431A (ja) | 治療薬剤としての二環式芳香族化合物 | |
DE60004066T2 (de) | Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten | |
CA2012628C (fr) | Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
CN103038229A (zh) | 杂芳基化合物及其使用方法 | |
CN101094852A (zh) | 作为cns活性剂的取代的吲嗪以及衍生物 | |
JP2001512727A (ja) | 5ht−1受容体のリガンドとしてのニ環式化合物 | |
EP1828125B1 (fr) | Derives d'arylpiperazine et leur utilisation comme ligands selectifs du recepteur d3 de la dopamine | |
JPH07188207A (ja) | 1−[2h−1−ベンゾピラン−2−オン−8−イル]−ピペラジン誘導体 | |
CN1049660C (zh) | 苯并吡喃化合物,它们的制备方法和含有它们的药物组合物 | |
DE60002583T2 (de) | Benzofurylpiperazine als serotonin-agonisten | |
CN1128030A (zh) | 具有中枢神经系统活性的杂环胺 | |
US20040039023A1 (en) | Therapeutic agents | |
CA2346506C (fr) | Derives d'aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone comme agonistes du recepteur 5-ht1 | |
KR20010052526A (ko) | 5-ht 수용체에 대해 친화성이 있는n-벤조디옥사닐메틸-1-피페리딜-메틸아민 화합물 | |
JPS62103078A (ja) | ヘテロ環式アミノ化合物 | |
JPH02289551A (ja) | ピリミジン誘導体を有効成分とする脳機能改善剤 | |
Gharagozloo | Synthesis of serotonergic agents | |
JPH09291090A (ja) | ピペリジノンおよびホモピペリジノン誘導体 | |
FR2630113A2 (fr) | Derives de ((piperidinyl-4)methyl)-2 tetrahydro-1,2,3,4 isoquinoleine, leur preparation et leur application en therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040316 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040611 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040726 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20041025 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20041130 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110416 Year of fee payment: 15 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120416 Year of fee payment: 16 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130416 Year of fee payment: 17 |